Rapport Therapeutics, Inc.·4

Jun 10, 5:46 PM ET

PAUL STEVEN M 4

Research Summary

AI-generated summary

Updated

Rapport Therapeutics (RAPP) Director Paul Steven M Receives Award

What Happened
Paul Steven M, a director of Rapport Therapeutics (RAPP), was granted a derivative award on 2026-06-10 covering 15,200 shares. The grant is reported at $0.00 on the Form 4 (derivative award), and the shares underlying the option will vest subject to continued service.

Key Details

  • Transaction date: 2026-06-10 (Form filed same day) — filing appears timely.
  • Transaction type: Grant / award of a derivative security (code A).
  • Amount: 15,200 shares; reported price/value: $0.00 on the filing.
  • Vesting: The shares underlying the option vest on the earlier of (i) June 10, 2027 or (ii) the date of the next Annual Meeting of stockholders, subject to the reporting person’s continued service. (Footnote F1)
  • Shares owned after transaction: Not specified in the provided excerpt — see the full Form 4 for total beneficial ownership.

Context
This was an award (option grant) to a director, not a purchase or sale. The award vests in the future if the director remains in service, so there was no immediate exercise or sale of shares. Director option grants are common as compensation and do not by themselves indicate an immediate trading signal.